NEW DELHI: Cognizant is advancing the appliance of generative AI know-how with the NVIDIA BioNeMo platform to unravel advanced challenges of drug discovery within the life sciences business. That is anticipated to enhance productiveness within the growth course of and improve the pace at which new, life-saving remedies might be dropped at market, says an organization assertion.
Conventional drug discovery methodologies are course of intensive and require the evaluation of huge repositories of scientific literature and scientific information in an effort to reveal related insights. Furthermore, conventional strategies are burdened with excessive prices and lengthy growth lifecycles with a excessive charge of failure. By leveraging gen AI applied sciences, scientific researchers can quickly sift by way of in depth datasets, extra precisely predict interactions between drug compounds and create new, viable drug growth pathways.
“Greater than some other technological breakthrough in latest many years, generative AI has the potential to revolutionize the way in which new medication are researched, developed and dropped at market, making the creation of lifesaving discoveries sooner, smarter and extra accessible to all,” mentioned Anna Elango, EVP, Cognizant’s Core Applied sciences & Insights. “By collaborating with NVIDIA, Cognizant can open the trail to realizing this imaginative and prescient safely, responsibly and cost-effectively for our life sciences shoppers.”
“Generative AI will drive the following wave of enterprise productiveness positive factors throughout industries, enabled by the NVIDIA AI Enterprise software program platform,” mentioned Alvin DaCosta, VP, world consulting accomplice group, NVIDIA.
Conventional drug discovery methodologies are course of intensive and require the evaluation of huge repositories of scientific literature and scientific information in an effort to reveal related insights. Furthermore, conventional strategies are burdened with excessive prices and lengthy growth lifecycles with a excessive charge of failure. By leveraging gen AI applied sciences, scientific researchers can quickly sift by way of in depth datasets, extra precisely predict interactions between drug compounds and create new, viable drug growth pathways.
“Greater than some other technological breakthrough in latest many years, generative AI has the potential to revolutionize the way in which new medication are researched, developed and dropped at market, making the creation of lifesaving discoveries sooner, smarter and extra accessible to all,” mentioned Anna Elango, EVP, Cognizant’s Core Applied sciences & Insights. “By collaborating with NVIDIA, Cognizant can open the trail to realizing this imaginative and prescient safely, responsibly and cost-effectively for our life sciences shoppers.”
“Generative AI will drive the following wave of enterprise productiveness positive factors throughout industries, enabled by the NVIDIA AI Enterprise software program platform,” mentioned Alvin DaCosta, VP, world consulting accomplice group, NVIDIA.
